TriLink's Investment Fuels RNA Innovation Center Establishment at Johns Hopkins University

TriLink Biotechnologies' investment enables the establishment of an RNA Innovation Center at Johns Hopkins University. The center will focus on advancing RNA-based therapies and technologies. TriLink's funding will support research, education, and collaboration, aiming to accelerate progress in RNA science and its applications for treating diseases.

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences, has teamed up with Johns Hopkins University to accelerate RNA therapeutics and discovery research. They're establishing a new center at the Johns Hopkins Whiting School of Engineering, utilizing TriLink's RNA synthesis technology.

TriLink is investing in the center, providing funding and access to their CleanScript technology to aid mRNA development. They'll also offer technical support and access to essential supplies for research and manufacturing.

Drew Burch from Maravai LifeSciences states that the collaboration demonstrates their dedication to advancing nucleic acid-based therapies. By sharing their expertise, they aim to equip Hopkins researchers with the necessary tools to develop advanced treatments.

The center's goal, according to Whiting School of Engineering's Dean Ed Schlesinger, is to revolutionize human health through RNA applications. Cutting-edge tools will foster innovation and expand Hopkins' RNA research community.

Jeff Coller, an expert in RNA biology and therapeutics, will lead the center, which will open this spring. It will unite Johns Hopkins experts across RNA biology, genetic medicine, drug delivery, and biotechnology, serving as a training hub for future RNA investigators and fostering collaboration among researchers from different disciplines.

Source: World pharma today